![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Department of Anesthesiology and Center for the Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina
Activation of adenosine A1 receptors by endogenous adenosine or synthetic
agonists produces antinociception in animal models of acute pain and also
reduces hypersensitivity in models of inflammatory and nerve-injury pain.
Allosteric adenosine modulators facilitate and potentate the action of
adenosine agonists at the A1 receptors. The purpose of the current study was
to examine the effect and site of action for an allosteric adenosine
modulator, T62 [2-amino-3-(4-chlorobenzoyl)-5,6,
7,8-tetrahydrobenzothiophene], in rat models of acute pain and inflammation.
Intrathecal (i.t.) T62 did not change the withdrawal latency or threshold of
normal rats to acute heat or to acute paw pressure. In contrast, i.t. T62
reversed thermal hypersensitivity in carrageenin-inflamed rats. Subcutaneous
(s.c.) injection of T62 into the inflamed paw had no such effect. To
investigate a potential site of action on nociceptors, single-unit afferent
activity to mechanical stimuli on A
- and C-fibers was examined in
normal or carrageenin-inflamed rats before and after intravenous (i.v.) T62
administration. Intravenous T62, 3 mg/kg, had no significant effect in either
normal or inflamed conditions. These results support previous studies to
suggest that adenosine receptor modulators lack efficacy to acute nociceptive
stimuli in the normal condition, but reduce hypersensitivity during
inflammation through a central mechanism.
Address correspondence to: Dr. Xinhui Li, Assistant Professor of Anesthesiology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-1009. E-mail: xli{at}wfubmc.edu